论文部分内容阅读
目的观察托拉塞米在终末期扩张型心肌病的临床应用效果。方法选取医院2015年收治的终末期扩张型心肌病患者60例,随机分为观察组和对照组各30例,给予60例患者心力衰竭基础治疗,在此基础上,观察组给予托拉塞米治疗,对照组给予呋塞米治疗,对比2组患者治疗期间的体质量变化,心功能分级,静脉血液中钾,钠水平,水肿程度,血管紧张素Ⅱ等临床评价终末期扩张型心肌病指标。结果服药治疗后观察组尿量增加量、心功能改善程度以及血浆肾素降低量均优于对照组,差异有统计学意义(P<0.05);观察组发生不良反应9例(30.0%),明显低于对照组的20例(66.7%),差异有统计学意义(P<0.05)。结论在终末期扩张型心肌病临床治疗过程中,托拉塞米联合心力衰竭基础治疗能够现状改善患者临床症状,降低不良反应发生率,提高患者的心脏功能以及生活水平,具有高安全性、高可靠性等特点,在临床实践中值得推广应用。
Objective To observe the clinical application of torsemide in patients with terminal dilated cardiomyopathy. Methods Sixty patients with end-stage dilated cardiomyopathy who were admitted to hospital in 2015 were randomly divided into observation group (30 cases) and control group (30 cases), and 60 cases were given basic treatment of heart failure. On this basis, the observation group received torsemide The control group was treated with furosemide. The changes of body weight, heart function classification, potassium and sodium levels in venous blood, degree of edema and angiotensin Ⅱ were compared between the two groups in the evaluation of end-stage dilated cardiomyopathy . Results After treatment, the increase of urinary volume, the improvement of cardiac function and the decrease of plasma renin in the observation group were better than those in the control group (P <0.05). Nine patients (30.0%) in the observation group had adverse reactions, Significantly lower than the control group of 20 cases (66.7%), the difference was statistically significant (P <0.05). Conclusion In the course of clinical treatment of end-stage dilated cardiomyopathy, torsemide combined with heart failure can improve clinical symptoms, reduce the incidence of adverse reactions, improve cardiac function and quality of life of patients with high safety and high Reliability and other characteristics, it is worth promoting in clinical practice.